|Board Biographies | Management Biographies | Governance Documents | Committee Composition|
SV Life Sciences
Mr. Burgess is Venture Partner at SV Life Sciences. Previously, he was President and Chief Executive Officer of Rempex Pharmaceuticals, an antibiotics company he co-founded in 2011 and subsequently sold to The Medicines Company in 2013. Prior to this, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, a company that advanced an inhaled antibiotic for cystic fibrosis into Phase 3 before it was acquired by Aptalis Inc. in 2011. Previously, he served as Chief Operating Officer and Chief Financial Officer of Hollis-Eden Pharmaceuticals, a public biotechnology company focused on biodefense, infectious diseases, and immune system disorders. Prior to this, Mr. Burgess spent 10 years at Gensia Sicor, Inc. (acquired by Teva Pharmaceutical Industries Ltd), where he held a variety of executive-level positions with responsibility for overall finance for the company. He began his career at Castle & Cooke, and Smith Barney, Harris Upham and Company. Mr. Burgess is Chairman of Atox Bio, and a Board member of Cidara Therapeutics, Arsanis, Arbutus Bio[harma Corp. and Pulmocide. He received a BA degree in economics from Stanford University and an MBA degree from Harvard Business School.
Axel Bolte currently serves as an investment advisor to HBM Partners AG, based in Zug, Switzerland. He has 16 years of experience in health care venture capital. Mr. Bolte was an investment manager at New Medical Technologies (NMT) AG, the first Swiss healthcare-focused venture capital firm. Since joining the private equity team at HBM Partners in 2003, he has led multiple biopharma investments. Previously, Mr. Bolte held a position in R&D management at Serono SA, Geneva. He currently serves or has served on the board of directors of various private and public biotechnology companies, including Adnexus Therapeutics (acquired by BMS), Kolltan Pharmaceuticals, Newron Pharmaceuticals (SWX: NWRN), PTC Therapeutics (NASDAQ:PTCT) and Ophthotech (NASDAQ: OPHT). Mr Bolte studied biochemistry and organic chemistry at the University of Cambridge, United Kingdom and the Swiss Federal Institute of Technology in Zurich, Switzerland, where he obtained an M.S. in biochemistry. He also obtained an MBA from the University of St. Gallen, Switzerland.
|Mark Corrigan, M.D.|
former President and Chief Executive Officer of Zalicus, Inc.
Dr. Corrigan is former President and Chief Executive Officer of Zalicus, Inc. Previously, Dr. Corrigan was Executive Vice President of Research and Development at the specialty pharmaceutical company Sepracor Inc., and prior to this, he spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before entering the healthcare industry, Dr. Corrigan was in academic research at the University of North Carolina at Chapel Hill School of Medicine, where he maintains a faculty appointment as Adjunct Professor in the Psychiatry Department. Dr. Corrigan served on the Board of Directors for Cubist Pharmaceuticals and of Avanir Pharmaceuticals prior to their acquisitions by Merck and Otsuka Holdings, respectively, and served as chairman of EPIRUS Biopharmaceuticals’ Board. Dr. Corrigan holds an M.D. degree from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University.
|Chau Quang Khuong|
OrbiMed Advisors LLC
Chau Quang Khuong has worked at OrbiMed Advisors LLC since 2003 and is currently a Private Equity Partner. Mr. Khuong gained experience in start-up operations and business development at Veritas Medicine, Inc. and in basic science research at the Yale School of Medicine and at Massachusetts General Hospital. He has been an active investor in antibiotics drug development companies. He currently serves as a director of several public and private companies, including Aerpio Therapeutics, Inc., Inspire Medical Systems, Cerapedics, Otonomy, Inc. (NASDAQ: OTIC), and Pieris Pharmaceuticals (NASDAQ: PIRS). He holds a B.S. in molecular, cellular and developmental biology with concentration in biotechnology and an MPH with concentration in infectious diseases, both from Yale University.
Mr. Webster is Chief Financial Officer of gene therapy company Spark Therapeutics. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc., a biotechnology company developing specialty drugs to treat gastrointestinal infections and related diseases, until its acquisition by Cubist Pharmaceuticals. Prior to this, Mr. Webster served as Senior Vice President and Chief Financial Officer of Adolor Corporation, also acquired by Cubist. Previously, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). He also was co-founder and served as President and Chief Executive Officer of Neuronyx, Inc., a biopharmaceutical company. Prior to this, Mr. Webster held positions of increasing responsibility, including as Director, Investment Banking Division, Health Care Group, for PaineWebber Incorporated. Mr. Webster holds an AB degree in economics cum laude from Dartmouth College and an MBA in finance from The Wharton School of the University of Pennsylvania.
Talbot Advisors LLC
George H. Talbot, M.D., FACP, FIDSA, an infectious diseases physician by training, began his pharmaceutical career in anti-infective drug development at Rhone-Poulenc Rorer, later Aventis. He founded his consultancy firm, Talbot Advisors LLC, in 2000. Dr. Talbot served as EVP and CMO of Cerexa (purchased by Forest Laboratories in 2007), and worked closely with Calixa Therapeutics (acquired by Cubist Pharmaceuticals, 2009) and Durata Therapeutics (purchased by Actavis Plc, 2014). In addition to his role on Nabriva’s Supervisory Board, he chairs its Clinical Advisory Board. Dr. Talbot was a founding member of IDSA's Antimicrobial Availability Task Force ("Bad Bugs, No Drugs"), and co-Chairs the ABSSSI/CABP and HABP/VABP Project Teams at the Biomarkers Consortium of the Foundation of the National Institutes of Health.
Aurinia Pharmaceuticals CEO
Charles A. Rowland, Jr., CPA, MBA is currently CEO of Aurinia Pharmaceuticals and is a member of the board of directors of Bind Therapeutics, Blueprint Pharmaceuticals and Vitae Pharmaceuticals. Charles was previously the VP and CFO of ViroPharma Inc., until it was acquired by Shire plc in January 2014. He has over 35 years of diversified experience in pharmaceutical operations and all areas of finance and accounting. Prior to joining ViroPharma in 2008, he was EVP and CFO, for Endo Pharmaceuticals, as well as, interim Co-CEO. Charles held positions of increasing responsibility at Biovail Corporation, Breakaway Technologies, Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. He holds an MBA from Rutgers University and a BS in Accounting from Saint Joseph's University.